January #98 : New Med on the Shelf - by Marissa Pareles

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Archives » POZ Magazine issues




Table of Contents

10 Ways to End AIDS (in 10 years)

Happy New You

Political Science

"Prevention" for Positives

Habitats for HIVers

On the Job

Going Under Cover

All the Right Places

2024: AIDS Cured, ex-PWAs Ignored

Trouble Indemnity

Earthwatch

Show & Gel

Healthful Humor

Living on Hope

Milestones

High Resolution: New Year’s Creeds

2004: What’s In, What’s Out?

Briefs

When Your CD4s Count

New Med on the Shelf

Quick Study: Virus in Vaginas

Strike a Pose

Chicago Hope?

Quick Study: Hep C

Watch Your Mouth

2X

CMV Drug Does Double Duty

Bed Head

Unreality TV

Mailbox

Publisher's Letter

Amazing Race



Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV


email print

January 2004

New Med on the Shelf

by Marissa Pareles

Lexiva (fosamprenavir calcium)
GlaxoSmithKline/Vertex


>>Class Protease inhibitor (PI).
A prodrug (meaning it improves absorption) of the PI Agenerase (amprenavir).

>>Task To stop HIV from reproducing.

>>Ticket About $730/month.

>>Pros First PI with no food or water restrictions. If you’re new to meds it can be taken as a once-daily with a Norvir (ritonavir) booster, or twice a day with or without the booster. (HAART old-timers take it twice a day with Norvir.) Fewer side effects and easier dosing than Agenerase.

>>Cons Sometimes needs the Norvir booster even if taken twice daily. Like other PIs, you can’t combine it with many drugs, including birth control pills. Can cause diarrhea, nausea, rash and, rarely, severe skin disease. Interaction and efficacy research isn’t finished.

>>HIV vets weigh in Treatment activists emphasize it’s not a new drug class—not even really a new drug. Tim Horn calls Lexiva “a slightly improved version of Agenerase (though there’s only been one short-term study comparing the two), with fewer pills and short-term side effects. It gives other PIs some competition in the convenience department.”




[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Poll
Are you buying holiday gifts that raise HIV/AIDS awareness?
Yes
No

Survey
Smoke Signals

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.